Glioblastoma (GBM) remains the most lethal and common primary brain tumor, even after
treatment with multiple therapies, such as surgical resection, chemotherapy, and radiation …

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors represent the standard of
care in patients with EGFR mutation-positive (EGFR m+) non-small cell lung cancer …

Introduction Limited clinical data are available regarding the efficacy of EGFR tyrosine
kinase inhibitors (EGFR TKIs) in patients with NSCLC harboring uncommon EGFR …

Glioblastoma multiforme (GBM) is amongst the deadliest of human cancers, with a median
survival rate of just over one year following diagnosis. Characterized by rapid proliferation …

The development of first-, second-, and third-generation epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of patients with non …

Lung cancer is the most commonly diagnosed cancer worldwide and it is also the most
leading cause of cancer-related deaths. Although multiple generations of targeted …

The past decades witnessed the clinical employment of targeted therapies including but not
limited to tyrosine kinase inhibitors (TKIs) that restrain a broad variety of pro-tumorigenic …

Epidermal growth factor receptor (EGFR) has been recognized as one of the attractive
targets for anticancer drug development. Herein, a set of anilino-1, 4-naphthoquinone …

Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are
standard of care for patients with EGFR mutation-positive non–small-cell lung cancer …

Adenocarcinoma is the most common type of non-small cell lung cancer. Some causative
genomic alterations in epidermal growth factor receptor (EGFR), including deletions in exon …